Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Proxor** is a fixed-dose pressurised metered-dose inhaler containing the inhaled corticosteroid beclometasone dipropionate and the long-acting beta-2 adrenergic agonist formoterol fumarate dihydrate. Beclometasone suppresses airway inflammation through glucocorticoid-receptor activation, while formoterol relaxes bronchial smooth muscle through beta-2 adrenergic receptor agonism. Thornton & Ross markets Proxor in the United Kingdom for adults with asthma; the 100/6 microgram strength is also indicated for chronic obstructive pulmonary disease. ([thorntonross.com](https://www.thorntonross.com/products/prescription/respiratory))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclometasone dipropionate + formoterol fumarate dihydrate.